These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27427876)

  • 1. Efavirenz is associated with higher bone mass in South African children with HIV.
    Arpadi SM; Shiau S; Strehlau R; Patel F; Mbete N; McMahon DJ; Kaufman JJ; Coovadia A; Kuhn L; Yin MT
    AIDS; 2016 Oct; 30(16):2459-2467. PubMed ID: 27427876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased bone turnover in HIV-infected children on antiretroviral therapy.
    Shiau S; Yin MT; Strehlau R; Patel F; Mbete N; Kuhn L; Coovadia A; Arpadi SM
    Arch Osteoporos; 2018 Apr; 13(1):40. PubMed ID: 29623447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
    BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study.
    Ramteke SM; Shiau S; Foca M; Strehlau R; Pinillos F; Patel F; Violari A; Liberty A; Coovadia A; Kuhn L; Arpadi SM;
    J Pediatric Infect Dis Soc; 2018 May; 7(2):143-150. PubMed ID: 28481997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
    Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
    Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy.
    Achan J; Kakuru A; Ikilezi G; Mwangwa F; Plenty A; Charlebois E; Young S; Havlir D; Kamya M; Ruel T
    Pediatr Infect Dis J; 2016 Dec; 35(12):1329-1332. PubMed ID: 27580060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.
    Dave JA; Cohen K; Micklesfield LK; Maartens G; Levitt NS
    PLoS One; 2015; 10(12):e0144286. PubMed ID: 26633015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
    Rojas J; Lonca M; Imaz A; Estrada V; Asensi V; Miralles C; Domingo P; Montero M; del Rio L; Fontdevila J; Perez I; Cruceta A; Gatell JM; Arnedo M; Martínez E
    HIV Med; 2016 May; 17(5):340-9. PubMed ID: 27089862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
    J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
    Gondrie IPE; Bastiaans DET; Fraaij PLA; Driessen GJA; van der Knaap LC; Visser EG; van Jaarsveld P; de Groot R; Hartwig NG; Burger DM; van Rossum AMC
    Pediatr Infect Dis J; 2017 Oct; 36(10):976-980. PubMed ID: 28475554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
    Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
    AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
    Meyers T; Sawry S; Wong JY; Moultrie H; Pinillos F; Fairlie L; van Zyl G
    Pediatr Infect Dis J; 2015 Feb; 34(2):175-9. PubMed ID: 25741970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
    Echeverría P; Negredo E; Carosi G; Gálvez J; Gómez JL; Ocampo A; Portilla J; Prieto A; López JC; Rubio R; Mariño A; Pedrol E; Viladés C; del Arco A; Moreno A; Bravo I; López-Blazquez R; Pérez-Alvarez N; Clotet B
    Antiviral Res; 2010 Feb; 85(2):403-8. PubMed ID: 19941906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
    Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH
    Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.